J J Biagi

Summary

Affiliation: Queen's University
Country: Canada

Publications

  1. ncbi request reprint Systemic treatment policies in ovarian cancer: the next 10 years
    J J Biagi
    Kingston Regional Cancer Centre, Kingston, ON, Canada
    Int J Gynecol Cancer 13:231-40. 2003
  2. doi request reprint A phase II study of sunitinib in patients with recurrent epithelial ovarian and primary peritoneal carcinoma: an NCIC Clinical Trials Group Study
    J J Biagi
    Department of Oncology, Cancer Centre of South Eastern Ontario, Kingston, Ontario, Canada
    Ann Oncol 22:335-40. 2011
  3. doi request reprint Association between time to initiation of adjuvant chemotherapy and survival in colorectal cancer: a systematic review and meta-analysis
    James J Biagi
    Department of Oncology, Queen s University, Kingston, Ontario, Canada
    JAMA 305:2335-42. 2011
  4. ncbi request reprint A phase II study of sunitinib (SU11248) in patients (pts) with recurrent epithelial ovarian, fallopian tube or primary peritoneal carcinoma - NCIC CTG IND 185
    J J Biagi
    Cancer Centre SE Ontario, Kingston, ON, Canada Princess Margaret Hospital, Toronto, ON, Canada Queen Elizabeth II Health Science Centre, Halifax, NS, Canada British Columbia Cancer Centre Southern Interior, Kelowna, BC, Canada British Columbia Cancer Centre Fraser Valley Centre, Surrey, BC, Canada NCIC Clinical Trials Group, Kingston, ON, Canada Cancer Therapy Evaluation Program NCI, Bethesda, MD
    J Clin Oncol 26:5522. 2008
  5. ncbi request reprint A phase II study of temsirolimus (CCI-779) in patients with metastatic and/or locally advanced recurrent endometrial cancer previously treated with chemotherapy: NCIC CTG IND 160b
    A M Oza
    NCIC Clinical Trials Group, Princess Margaret Hospital, University of Toronto, Toronto, ON, Canada Juravinski Cancer Centre, Hamilton, ON, Canada Centre Hospitalier de l Université de Montréal, Montreal, QC, Canada Cancer Centre of Southeastern Ontario at Kingston, Kingston, ON, Canada McGill University, Montreal, QC, Canada NCIC Clinical Trials Group, Kingston, ON, Canada National Cancer Institute, Bethesda, MD
    J Clin Oncol 26:5516. 2008
  6. ncbi request reprint Decreased dose density of standard chemotherapy does not compromise survival for ovarian cancer patients
    A Molckovsky
    Department of Oncology and Department of Obstetrics and Gynecology, Queen s University, Kingston, Ontario, Canada
    Int J Gynecol Cancer 18:8-13. 2008
  7. ncbi request reprint A phase II study of cediranib (AZD2171) in recurrent or persistent ovarian, peritoneal or fallopian tube cancer: Final results of a PMH, Chicago and California consortia trial
    H W Hirte
    Juravinski Cancer Centre, Hamilton, ON, Canada Princess Margaret Hospital, Toronto, ON, Canada University of Chicago Medical Center, Chicago, IL London Health Sciences Centre, London, ON, Canada City of Hope Medical Center, Duarte, CA Cancer Centre of Southeastern Ontario, Kingston, ON, Canada National Cancer Institute, Bethesda, MD
    J Clin Oncol 26:5521. 2008
  8. ncbi request reprint A phase II study of dexamethasone, ifosfamide, cisplatin and etoposide (DICE) as salvage chemotherapy for patients with relapsed and refractory lymphoma
    J J Biagi
    Department of Hematology, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia
    Leuk Lymphoma 46:197-206. 2005

Detail Information

Publications8

  1. ncbi request reprint Systemic treatment policies in ovarian cancer: the next 10 years
    J J Biagi
    Kingston Regional Cancer Centre, Kingston, ON, Canada
    Int J Gynecol Cancer 13:231-40. 2003
    ..New standards of care and treatment policies in the next decade will be based on high-quality evidence of improved survival from controlled studies. Many such trials are now ongoing or planned...
  2. doi request reprint A phase II study of sunitinib in patients with recurrent epithelial ovarian and primary peritoneal carcinoma: an NCIC Clinical Trials Group Study
    J J Biagi
    Department of Oncology, Cancer Centre of South Eastern Ontario, Kingston, Ontario, Canada
    Ann Oncol 22:335-40. 2011
    ..Sunitinib is a multitargeted receptor tyrosine kinase inhibitor. We conducted a two-stage phase II study to evaluate the objective response rate of oral sunitinib in recurrent epithelial ovarian cancer...
  3. doi request reprint Association between time to initiation of adjuvant chemotherapy and survival in colorectal cancer: a systematic review and meta-analysis
    James J Biagi
    Department of Oncology, Queen s University, Kingston, Ontario, Canada
    JAMA 305:2335-42. 2011
    ..Adjuvant chemotherapy (AC) improves survival among patients with resected colorectal cancer. However, the optimal timing from surgery to initiation of AC is unknown...
  4. ncbi request reprint A phase II study of sunitinib (SU11248) in patients (pts) with recurrent epithelial ovarian, fallopian tube or primary peritoneal carcinoma - NCIC CTG IND 185
    J J Biagi
    Cancer Centre SE Ontario, Kingston, ON, Canada Princess Margaret Hospital, Toronto, ON, Canada Queen Elizabeth II Health Science Centre, Halifax, NS, Canada British Columbia Cancer Centre Southern Interior, Kelowna, BC, Canada British Columbia Cancer Centre Fraser Valley Centre, Surrey, BC, Canada NCIC Clinical Trials Group, Kingston, ON, Canada Cancer Therapy Evaluation Program NCI, Bethesda, MD
    J Clin Oncol 26:5522. 2008
    ....
  5. ncbi request reprint A phase II study of temsirolimus (CCI-779) in patients with metastatic and/or locally advanced recurrent endometrial cancer previously treated with chemotherapy: NCIC CTG IND 160b
    A M Oza
    NCIC Clinical Trials Group, Princess Margaret Hospital, University of Toronto, Toronto, ON, Canada Juravinski Cancer Centre, Hamilton, ON, Canada Centre Hospitalier de l Université de Montréal, Montreal, QC, Canada Cancer Centre of Southeastern Ontario at Kingston, Kingston, ON, Canada McGill University, Montreal, QC, Canada NCIC Clinical Trials Group, Kingston, ON, Canada National Cancer Institute, Bethesda, MD
    J Clin Oncol 26:5516. 2008
    ..This trial was designed to assess the level of activity in patients who had previously received chemotherapy...
  6. ncbi request reprint Decreased dose density of standard chemotherapy does not compromise survival for ovarian cancer patients
    A Molckovsky
    Department of Oncology and Department of Obstetrics and Gynecology, Queen s University, Kingston, Ontario, Canada
    Int J Gynecol Cancer 18:8-13. 2008
    ..These results suggest that decreasing the frequency of chemotherapy cycles does not decrease survival. Prospective trials would be required to compare quality of life and cost-effectiveness...
  7. ncbi request reprint A phase II study of cediranib (AZD2171) in recurrent or persistent ovarian, peritoneal or fallopian tube cancer: Final results of a PMH, Chicago and California consortia trial
    H W Hirte
    Juravinski Cancer Centre, Hamilton, ON, Canada Princess Margaret Hospital, Toronto, ON, Canada University of Chicago Medical Center, Chicago, IL London Health Sciences Centre, London, ON, Canada City of Hope Medical Center, Duarte, CA Cancer Centre of Southeastern Ontario, Kingston, ON, Canada National Cancer Institute, Bethesda, MD
    J Clin Oncol 26:5521. 2008
    ..A two-stage, multicentre phase 2 clinical trial was initiated to evaluate the activity of cediranib in patients (pts) with recurrent ovarian, peritoneal or fallopian tube cancer...
  8. ncbi request reprint A phase II study of dexamethasone, ifosfamide, cisplatin and etoposide (DICE) as salvage chemotherapy for patients with relapsed and refractory lymphoma
    J J Biagi
    Department of Hematology, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia
    Leuk Lymphoma 46:197-206. 2005
    ..Further clinical studies of DICE in first relapse and in older patients, possibly with the addition of rituximab, are warranted...